This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Abdallah Souabni: Innovator in Cancer Treatment
Introduction
Abdallah Souabni is a prominent inventor based in Vienna, Austria. He has made significant contributions to the field of medicine, particularly in the development of innovative treatments for cancer. His work focuses on creating binding molecules that target specific proteins involved in cancer progression.
Latest Patents
Abdallah Souabni holds a patent for "Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer." This invention relates to binding molecules that specifically bind to CD137 and FAP, offering potential applications in medical treatments. The patent outlines pharmaceutical compositions containing these molecules and methods for their use as agents for the treatment and prevention of cancer. He has 1 patent to his name.
Career Highlights
Abdallah is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His role involves research and development aimed at advancing cancer therapies. His expertise and innovative approach have positioned him as a valuable asset in the field of oncology.
Collaborations
Abdallah has collaborated with notable colleagues, including Eric Borges and Pankaj Gupta. These partnerships enhance the research efforts and contribute to the development of effective cancer treatments.
Conclusion
Abdallah Souabni's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. His contributions through patents and collaborations highlight the importance of research in developing new therapeutic options.